| 1.77 -0.04 (-2.21%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.16 |
1-year : | 2.33 |
| Resists | First : | 1.85 |
Second : | 2 |
| Pivot price | 1.74 |
|||
| Supports | First : | 1.61 |
Second : | 1.33 |
| MAs | MA(5) : | 1.73 |
MA(20) : | 1.77 |
| MA(100) : | 1.78 |
MA(250) : | 2.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.3 |
D(3) : | 28.9 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 5.65 | Low : | 1.45 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SEER ] has closed below upper band by 36.0%. Bollinger Bands are 42% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.8 - 1.81 | 1.81 - 1.82 |
| Low: | 1.71 - 1.72 | 1.72 - 1.73 |
| Close: | 1.75 - 1.77 | 1.77 - 1.79 |
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Fri, 12 Apr 2024
Seer, Inc. (NASDAQ:SEER) is a favorite amongst institutional investors who own 51% - Yahoo Finance
Fri, 01 Mar 2024
Earnings call: Seer reports growth and outlines future proteomics strategy - Investing.com
Thu, 29 Feb 2024
Seer Inc (SEER) Reports Mixed Financial Results for Q4 and Full Year 2023 - Yahoo Finance
Thu, 29 Feb 2024
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook - GlobeNewswire
Fri, 09 Feb 2024
Seer ProteographTM Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies - Technology Networks
Thu, 08 Feb 2024
Zoom Video And 2 Other Stocks Insiders Are Selling - Procore Technologies (NYSE:PCOR), Seer (NASDAQ:SEER) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 71.5 (%) |
| Shares Short | 2,760 (K) |
| Shares Short P.Month | 2,350 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.17 |
| Profit Margin | 0 % |
| Operating Margin | -501 % |
| Return on Assets (ttm) | -14 % |
| Return on Equity (ttm) | -20.5 % |
| Qtrly Rev. Growth | -3.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -1.32 |
| PEG Ratio | 0.1 |
| Price to Book value | 0.28 |
| Price to Sales | 6.45 |
| Price to Cash Flow | -1.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|